122 related articles for article (PubMed ID: 9510503)
21. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
22. The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat.
Los G; Mutsaers PH; Ruevekamp M; McVie JG
Cancer Lett; 1990 May; 51(2):109-17. PubMed ID: 2344588
[TBL] [Abstract][Full Text] [Related]
23. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
24. Absorption, distribution and excretion of beta-cyclodextrin and glucosyl-beta-cyclodextrin in rats.
Kubota Y; Fukuda M; Muroguchi M; Koizumi K
Biol Pharm Bull; 1996 Aug; 19(8):1068-72. PubMed ID: 8874818
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS.
Zhao D; Zhang Y; Xu C; Dong C; Lin H; Zhang L; Li C; Ren S; Wang X; Yang S; Han D; Chen X
Biol Trace Elem Res; 2012 Aug; 148(2):203-8. PubMed ID: 22367705
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
[TBL] [Abstract][Full Text] [Related]
27. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers.
Kidani Y; Noji M; Tashiro T
Gan; 1980 Oct; 71(5):637-43. PubMed ID: 7227714
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
30. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
[TBL] [Abstract][Full Text] [Related]
31. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
32. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine.
Binks SP; Dobrota M
Biochem Pharmacol; 1990 Sep; 40(6):1329-36. PubMed ID: 2206139
[TBL] [Abstract][Full Text] [Related]
33. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
34. The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administration.
Tinker N; De Spiegeleer B; Sharma H; Jackson H; McAuliffe C; Reman JP
Int J Rad Appl Instrum B; 1990; 17(4):427-36. PubMed ID: 2201668
[TBL] [Abstract][Full Text] [Related]
35. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.
Pendyala L; Kidani Y; Perez R; Wilkes J; Bernacki RJ; Creaven PJ
Cancer Lett; 1995 Nov; 97(2):177-84. PubMed ID: 7497460
[TBL] [Abstract][Full Text] [Related]
37. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
[TBL] [Abstract][Full Text] [Related]
38. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration.
Yano H; Hirayama F; Kamada M; Arima H; Uekama K
J Control Release; 2002 Feb; 79(1-3):103-12. PubMed ID: 11853922
[TBL] [Abstract][Full Text] [Related]
39. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of l-OHP in mice.
Mathé G; Kidani Y; Noji M; Maral R; Bourut C; Chenu E
Cancer Lett; 1985 Jun; 27(2):135-43. PubMed ID: 4039973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
